USA allowance for the FXR agonist use patent in HBV

ENYO Pharma got the USA allowance for its FXR agonist use patent in hepatitis B virus (HBV). The patent was licensed under exclusive agreement from Inserm. FXR agonists change the composition of the transcriptional complex on the HBV cccDNA resulting in repression of HBV cccDNA expression.

Read next in 'Latest news'